Scott T. Tagawa

Research interests

Publications

• European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update

  European Urology · 2023 · https://doi.org/10.1016/j.eururo.2023.02.027

• Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(21)00660-4

• Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(21)00660-4

• Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2107322

• TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

  Journal of Clinical Oncology · 2021 · 10.1200/jco.20.03489

• Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30541-6

• Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling

  Nature Communications · 2019 · https://doi.org/10.1038/s41467-019-10873-y

• Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1817323

• Clinical features of neuroendocrine prostate cancer

  European Journal of Cancer · 2019 · 10.1016/j.ejca.2019.08.011

• Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

  Journal of Clinical Oncology · 2019 · 10.1200/jco.18.01731

• Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer

  Science Translational Medicine · 2019 · https://doi.org/10.1126/scitranslmed.aav0891

• A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers

  Clinical Cancer Research · 2018 · 10.1158/1078-0432.ccr-18-1912

• Patient derived organoids to model rare prostate cancer phenotypes

  Nature Communications · 2018 · 10.1038/s41467-018-04495-z

• Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.18.00606

• Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

  Nature Medicine · 2016 · https://doi.org/10.1038/nm.4045

• Clonal evolution of chemotherapy-resistant urothelial carcinoma

  Nature Genetics · 2016 · 10.1038/ng.3692

• Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response

  JAMA Oncology · 2015 · 10.1001/jamaoncol.2015.1313

• Integrative Clinical Genomics of Advanced Prostate Cancer

  Cell · 2015 · https://doi.org/10.1016/j.cell.2015.05.001

• Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer

  Neoplasia · 2013 · 10.1593/neo.121550

• Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

  Clinical Cancer Research · 2013 · 10.1158/1078-0432.ccr-13-0231

• Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2011.41.5166

• Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity

  European Urology · 2012 · 10.1016/j.eururo.2012.08.053

• Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

  Cancer Research · 2011 · 10.1158/0008-5472.can-11-1417

• Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

  Cancer Discovery · 2011 · https://doi.org/10.1158/2159-8290.cd-11-0130

• Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody

  Lab on a Chip · 2009 · 10.1039/b917959c

Current projects

No projects listed.